**Chief Physician** **Major Social Affiliations:** Vice Chairman, Thoracic Precision Treatment Committee, Chinese Geriatric Health Association; Vice Chairman, Lung Cancer Committee, Beijing Chronic Disease Prevention and Health Education Research Association; Vice President, Oncology Branch, Chinese Ethnic Medicine Association; Standing Committee Member, Tumor Chemotherapy Committee, China Medical Education Association; Standing Committee Member, Lung Cancer Control and Prevention Branch, China International Exchange and Promotive Association for Medical and Health Care. **Representative Achievements:** **Major Publications:** (*Corresponding Author) 1. Tongtong An, Shuhang Wang, Jie Wang, et al. Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res 2010;16:1324-1330. 2. An Tongtong, Liu Xuyi, Fang Jian, Wu Meina, et al. Randomized Comparison of Ondansetron versus Metoclopramide Combined with Low-Dose Dexamethasone in Controlling Delayed Emesis Induced by High-Dose Cisplatin-Based Chemotherapy. Chinese Journal of Clinical Oncology, 2002, Vol. 29, Issue 08. 3. An Tongtong, Liu Xuyi, Fang Jian, Wang Jie, et al. Prognostic Analysis of Primary Site Radiotherapy during Chemotherapy in 188 Patients with Stage IV Non-Small Cell Lung Cancer. Chinese Journal of Clinical Oncology, 2007, Vol. 34, Issue 21. 4. An Tongtong, Huang Zhen, Wang Yuyan, Wang Zhijie, Bai Hua, Wang Jie. Efficacy Observation of Re-administration of EGFR-TKI after Initial Treatment in Advanced Non-Small Cell Lung Cancer. Chinese Journal of Lung Cancer, 2011, 3(14): 261-265. 5. TT An, JC Duan, MN Wu, Y Lu, Jie Wang. Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer. Chinese Journal of Tuberculosis & Respiratory Diseases, 2012, 35(5): 323-8.